JCEM:甲状腺功能正常老年人血清促甲状腺激素与手握力的关系

2018-08-18 xing.T MedSci原创

由此可见,这些结果表明位于参考范围下限的血清TSH水平可能与低肌肉力量有关,特别是在老年男性中。

尽管甲亢甚至亚临床甲亢会导致明显的肌肉无力,但正常参考范围内甲状腺功能对肌肉力量的影响尚不清楚。近日,内分泌和代谢性疾病领域权威杂志Journal of Clinical Endocrinology & Metabolism上发表了一篇研究文章,该研究旨在调查甲状腺功能正常的老人血清促甲状腺激素(TSH)和游离T4水平与手部握力(HGS)之间的关系。

该研究为来自韩国国家健康和营养调查的全国代表性人口横断面研究。参与者为650名年龄≥50岁的男性和533名绝经后女性。该研究的主要观察指标为使用数字握力计测量的HGS,并且基于HGS的韩国特定截止点(男性和女性分别为28.9和16.8kg)定义低肌肉强度。

在调整混杂因素后,降低血清TSH而不是游离T4水平与男性HGS较低相关(P=0.032)。与具有较高正常TSH水平的男性相比,具有较低正常TSH水平的男性显示HGS降低5.0%(P=0.027),随着血清TSH四分位数的降低,HGS线性降低(趋势P=0.018)。肌肉力量较低的男性血清TSH水平比肌肉力量正常参与者低22.0%(P=0.015),较低正常TSH水平的男性出现低肌肉力量的几率比较高正常TSH水平的男性要低3.76倍(P=0.021)。然而,在绝经后妇女中未观察到这些相关性。

由此可见,这些结果表明位于参考范围下限的血清TSH水平可能与低肌肉力量有关,特别是在老年男性中。

原始出处:

Beom-Jun Kim,et al. Association of serum thyroid-stimulating hormone with hand grip strength in community-dwelling euthyroid elderly.J Clin Endocrinol Metab. 2018. https://doi.org/10.1210/jc.2018-01095

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2063204, encodeId=230320632048d, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Wed Oct 10 00:58:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724843, encodeId=db111e248430c, content=<a href='/topic/show?id=7b3b56865d3' target=_blank style='color:#2F92EE;'>#握力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56865, encryptionId=7b3b56865d3, topicName=握力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e60333711340, createdName=syscxl, createdTime=Sun Nov 25 16:58:00 CST 2018, time=2018-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009047, encodeId=e907200904ee6, content=<a href='/topic/show?id=f8a369865df' target=_blank style='color:#2F92EE;'>#甲状腺功能正常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69865, encryptionId=f8a369865df, topicName=甲状腺功能正常)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sat Sep 15 15:58:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777822, encodeId=f1031e7782243, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Sat Aug 03 12:58:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360276, encodeId=eba913602e62f, content=<a href='/topic/show?id=b0dc2e097bf' target=_blank style='color:#2F92EE;'>#促甲状腺激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27097, encryptionId=b0dc2e097bf, topicName=促甲状腺激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Mon Aug 20 03:58:00 CST 2018, time=2018-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339348, encodeId=6cb7339348f7, content=学习了,涨知识,值得借鉴的临床经验,获益匪浅,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/27/c53a212859edcad4f60a54feffff50bb.jpg, createdBy=67cf1525321, createdName=13718711b3m, createdTime=Sat Aug 18 13:40:50 CST 2018, time=2018-08-18, status=1, ipAttribution=)]
    2018-10-10 achengzhao
  2. [GetPortalCommentsPageByObjectIdResponse(id=2063204, encodeId=230320632048d, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Wed Oct 10 00:58:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724843, encodeId=db111e248430c, content=<a href='/topic/show?id=7b3b56865d3' target=_blank style='color:#2F92EE;'>#握力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56865, encryptionId=7b3b56865d3, topicName=握力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e60333711340, createdName=syscxl, createdTime=Sun Nov 25 16:58:00 CST 2018, time=2018-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009047, encodeId=e907200904ee6, content=<a href='/topic/show?id=f8a369865df' target=_blank style='color:#2F92EE;'>#甲状腺功能正常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69865, encryptionId=f8a369865df, topicName=甲状腺功能正常)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sat Sep 15 15:58:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777822, encodeId=f1031e7782243, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Sat Aug 03 12:58:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360276, encodeId=eba913602e62f, content=<a href='/topic/show?id=b0dc2e097bf' target=_blank style='color:#2F92EE;'>#促甲状腺激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27097, encryptionId=b0dc2e097bf, topicName=促甲状腺激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Mon Aug 20 03:58:00 CST 2018, time=2018-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339348, encodeId=6cb7339348f7, content=学习了,涨知识,值得借鉴的临床经验,获益匪浅,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/27/c53a212859edcad4f60a54feffff50bb.jpg, createdBy=67cf1525321, createdName=13718711b3m, createdTime=Sat Aug 18 13:40:50 CST 2018, time=2018-08-18, status=1, ipAttribution=)]
    2018-11-25 syscxl
  3. [GetPortalCommentsPageByObjectIdResponse(id=2063204, encodeId=230320632048d, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Wed Oct 10 00:58:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724843, encodeId=db111e248430c, content=<a href='/topic/show?id=7b3b56865d3' target=_blank style='color:#2F92EE;'>#握力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56865, encryptionId=7b3b56865d3, topicName=握力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e60333711340, createdName=syscxl, createdTime=Sun Nov 25 16:58:00 CST 2018, time=2018-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009047, encodeId=e907200904ee6, content=<a href='/topic/show?id=f8a369865df' target=_blank style='color:#2F92EE;'>#甲状腺功能正常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69865, encryptionId=f8a369865df, topicName=甲状腺功能正常)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sat Sep 15 15:58:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777822, encodeId=f1031e7782243, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Sat Aug 03 12:58:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360276, encodeId=eba913602e62f, content=<a href='/topic/show?id=b0dc2e097bf' target=_blank style='color:#2F92EE;'>#促甲状腺激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27097, encryptionId=b0dc2e097bf, topicName=促甲状腺激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Mon Aug 20 03:58:00 CST 2018, time=2018-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339348, encodeId=6cb7339348f7, content=学习了,涨知识,值得借鉴的临床经验,获益匪浅,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/27/c53a212859edcad4f60a54feffff50bb.jpg, createdBy=67cf1525321, createdName=13718711b3m, createdTime=Sat Aug 18 13:40:50 CST 2018, time=2018-08-18, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2063204, encodeId=230320632048d, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Wed Oct 10 00:58:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724843, encodeId=db111e248430c, content=<a href='/topic/show?id=7b3b56865d3' target=_blank style='color:#2F92EE;'>#握力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56865, encryptionId=7b3b56865d3, topicName=握力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e60333711340, createdName=syscxl, createdTime=Sun Nov 25 16:58:00 CST 2018, time=2018-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009047, encodeId=e907200904ee6, content=<a href='/topic/show?id=f8a369865df' target=_blank style='color:#2F92EE;'>#甲状腺功能正常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69865, encryptionId=f8a369865df, topicName=甲状腺功能正常)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sat Sep 15 15:58:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777822, encodeId=f1031e7782243, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Sat Aug 03 12:58:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360276, encodeId=eba913602e62f, content=<a href='/topic/show?id=b0dc2e097bf' target=_blank style='color:#2F92EE;'>#促甲状腺激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27097, encryptionId=b0dc2e097bf, topicName=促甲状腺激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Mon Aug 20 03:58:00 CST 2018, time=2018-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339348, encodeId=6cb7339348f7, content=学习了,涨知识,值得借鉴的临床经验,获益匪浅,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/27/c53a212859edcad4f60a54feffff50bb.jpg, createdBy=67cf1525321, createdName=13718711b3m, createdTime=Sat Aug 18 13:40:50 CST 2018, time=2018-08-18, status=1, ipAttribution=)]
    2019-08-03 smallant2015
  5. [GetPortalCommentsPageByObjectIdResponse(id=2063204, encodeId=230320632048d, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Wed Oct 10 00:58:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724843, encodeId=db111e248430c, content=<a href='/topic/show?id=7b3b56865d3' target=_blank style='color:#2F92EE;'>#握力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56865, encryptionId=7b3b56865d3, topicName=握力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e60333711340, createdName=syscxl, createdTime=Sun Nov 25 16:58:00 CST 2018, time=2018-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009047, encodeId=e907200904ee6, content=<a href='/topic/show?id=f8a369865df' target=_blank style='color:#2F92EE;'>#甲状腺功能正常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69865, encryptionId=f8a369865df, topicName=甲状腺功能正常)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sat Sep 15 15:58:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777822, encodeId=f1031e7782243, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Sat Aug 03 12:58:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360276, encodeId=eba913602e62f, content=<a href='/topic/show?id=b0dc2e097bf' target=_blank style='color:#2F92EE;'>#促甲状腺激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27097, encryptionId=b0dc2e097bf, topicName=促甲状腺激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Mon Aug 20 03:58:00 CST 2018, time=2018-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339348, encodeId=6cb7339348f7, content=学习了,涨知识,值得借鉴的临床经验,获益匪浅,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/27/c53a212859edcad4f60a54feffff50bb.jpg, createdBy=67cf1525321, createdName=13718711b3m, createdTime=Sat Aug 18 13:40:50 CST 2018, time=2018-08-18, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2063204, encodeId=230320632048d, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Wed Oct 10 00:58:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724843, encodeId=db111e248430c, content=<a href='/topic/show?id=7b3b56865d3' target=_blank style='color:#2F92EE;'>#握力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56865, encryptionId=7b3b56865d3, topicName=握力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e60333711340, createdName=syscxl, createdTime=Sun Nov 25 16:58:00 CST 2018, time=2018-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009047, encodeId=e907200904ee6, content=<a href='/topic/show?id=f8a369865df' target=_blank style='color:#2F92EE;'>#甲状腺功能正常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69865, encryptionId=f8a369865df, topicName=甲状腺功能正常)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sat Sep 15 15:58:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777822, encodeId=f1031e7782243, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Sat Aug 03 12:58:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360276, encodeId=eba913602e62f, content=<a href='/topic/show?id=b0dc2e097bf' target=_blank style='color:#2F92EE;'>#促甲状腺激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27097, encryptionId=b0dc2e097bf, topicName=促甲状腺激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Mon Aug 20 03:58:00 CST 2018, time=2018-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339348, encodeId=6cb7339348f7, content=学习了,涨知识,值得借鉴的临床经验,获益匪浅,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/27/c53a212859edcad4f60a54feffff50bb.jpg, createdBy=67cf1525321, createdName=13718711b3m, createdTime=Sat Aug 18 13:40:50 CST 2018, time=2018-08-18, status=1, ipAttribution=)]
    2018-08-18 13718711b3m

    学习了,涨知识,值得借鉴的临床经验,获益匪浅,谢谢分享

    0

相关资讯

J Hypertens:甲状腺功能正常个体甲状腺刺激素与高血压风险之间的剂量-反应关系

由此可见,当前的研究为甲状腺功能正常的个体血清TSH水平与高血压风险之间的剂量-反应关系提供了有力的证据。TSH水平较高的正常甲状腺功能正常个体发生高血压的风险高于正常TSH水平的个体。